Evolent Health's (EVH) IPG Acquisition Boosts Profits and is Margin Accretive - Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity analyst Richard Close reiterated a Buy rating and $45.00 price target on Evolent Health (NYSE: EVH) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
